Neurobo Pharmaceuticals Correlations
NRBO Stock | USD 2.35 0.05 2.08% |
The current 90-days correlation between Neurobo Pharmaceuticals and ZyVersa Therapeutics is 0.02 (i.e., Significant diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Neurobo Pharmaceuticals Correlation With Market
Weak diversification
The correlation between Neurobo Pharmaceuticals and DJI is 0.39 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Neurobo Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
Neurobo |
Moving together with Neurobo Stock
0.68 | VRAX | Virax Biolabs Group | PairCorr |
0.71 | VRPX | Virpax Pharmaceuticals | PairCorr |
0.63 | DYN | Dyne Therapeutics | PairCorr |
0.79 | XFOR | X4 Pharmaceuticals | PairCorr |
0.7 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.82 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.67 | INZY | Inozyme Pharma | PairCorr |
0.84 | KURA | Kura Oncology | PairCorr |
0.64 | PALI | Palisade Bio | PairCorr |
0.74 | STOK | Stoke Therapeutics | PairCorr |
0.83 | BDRX | Biodexa Pharmaceticals Upward Rally | PairCorr |
0.65 | TERN | Terns Pharmaceuticals | PairCorr |
0.7 | PPERY | Bank Mandiri Persero | PairCorr |
0.72 | PPERF | Bank Mandiri Persero | PairCorr |
0.68 | BKRKF | PT Bank Rakyat | PairCorr |
Moving against Neurobo Stock
0.83 | EWTX | Edgewise Therapeutics | PairCorr |
0.76 | PRAX | Praxis Precision Med | PairCorr |
0.74 | AMLX | Amylyx Pharmaceuticals | PairCorr |
0.69 | AKRO | Akero Therapeutics | PairCorr |
0.68 | ALVO | Alvotech | PairCorr |
0.64 | VRDN | Viridian Therapeutics | PairCorr |
0.49 | CRNX | Crinetics Pharmaceuticals | PairCorr |
0.42 | NTRB | Nutriband | PairCorr |
0.37 | BMEA | Biomea Fusion | PairCorr |
0.89 | SSNLF | Samsung Electronics | PairCorr |
0.87 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
0.83 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
0.81 | PTAIF | PT Astra International | PairCorr |
0.81 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
0.81 | HD | Home Depot | PairCorr |
0.78 | WMT | Walmart Aggressive Push | PairCorr |
0.78 | XOM | Exxon Mobil Corp Aggressive Push | PairCorr |
Related Correlations Analysis
0.68 | -0.08 | 0.34 | -0.19 | -0.05 | ZVSA | ||
0.68 | 0.03 | 0.55 | -0.22 | -0.02 | SONN | ||
-0.08 | 0.03 | 0.25 | 0.54 | 0.29 | ZURA | ||
0.34 | 0.55 | 0.25 | 0.14 | -0.14 | PHIO | ||
-0.19 | -0.22 | 0.54 | 0.14 | -0.03 | RNAZ | ||
-0.05 | -0.02 | 0.29 | -0.14 | -0.03 | QNRX | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Neurobo Stock performing well and Neurobo Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Neurobo Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
ZVSA | 4.67 | (0.99) | 0.00 | 0.60 | 0.00 | 9.17 | 78.93 | |||
SONN | 4.76 | (0.77) | 0.00 | 2.19 | 0.00 | 12.31 | 37.58 | |||
ZURA | 3.78 | (0.36) | 0.00 | (0.09) | 0.00 | 7.95 | 30.69 | |||
PHIO | 4.53 | (0.30) | 0.00 | (0.18) | 0.00 | 11.78 | 36.22 | |||
RNAZ | 7.63 | 1.05 | 0.10 | (0.44) | 6.52 | 22.00 | 68.80 | |||
QNRX | 6.21 | 0.47 | 0.07 | 0.37 | 6.73 | 17.65 | 74.46 |
Neurobo Pharmaceuticals Corporate Management
PharmD BCPS | VP Operations | Profile | |
Robert Homolka | Senior Operations | Profile | |
Ben MD | CEO Pres | Profile | |
Frank Kondrad | VP Devel | Profile | |
MiKyung Kim | Chief Officer | Profile |